Trial Profile
Phase II Study of SOM230 LAR in Combination With Bortezomib and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Pasireotide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 31 Jan 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 06 Jan 2012 Planned End Date changed from 1 Apr 2016 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 06 Jan 2012 Planned initiation date changed from 1 Sep 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.